billHR7875Event Monday, March 9, 2026Analyzed

To amend the Public Health Service Act to establish a grant program for providing services to individuals experiencing gambling addiction.

Neutral

Summary

HR7875 (POINTS Act of 2026) is a bill in the earliest legislative stage authorizing a grant program for gambling addiction services, but it has no appropriated funding and zero near-term market impact. The bill was introduced on 2026-03-09 and referred to committee with no further action. No publicly traded company is directly or materially affected at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR7875 is at the earliest legislative stage with zero appropriated funding and no specified authorization amount.
  • 2.No publicly traded company is named or directly affected by this bill in its current form.
  • 3.Investors should monitor for committee markup or a Senate companion bill before considering any sector impact.

Market Implications

No near-term market implications. This bill is procedural and has not moved since introduction over a month ago. No tickers are actionable based on this legislation at this time.

Full Analysis

What happened: Rep. Houchin (R-IN) introduced HR7875, the POINTS Act of 2026, on March 9, 2026, which would amend the Public Health Service Act to establish a competitive grant program for states, Tribes, and Tribal organizations to provide prevention, screening, treatment, and support services for gambling addiction. The bill has three cosponsors and was referred to the House Committee on Energy and Commerce.

Current status: The bill is in the earliest legislative stage — introduced and referred to committee. It has not been marked up, reported out, or voted on. No companion bill exists in the Senate. The legislative path is long and uncertain: it must pass committee, pass the House, pass the Senate, and be signed into law.

Money trail: Authorization vs Appropriation — The bill authorizes a grant program but does NOT specify any dollar amount. Section 554 describes what the program would do but does not include an authorized funding level. This means even if the bill became law, it would require a separate appropriations bill to allocate actual funds. Since no dollar amount is specified and no funding has been appropriated, the financial impact on any sector or company is effectively zero at this stage.

Winners and losers: At this procedural stage, there are no identifiable winners or losers among publicly traded companies. If the bill were to advance, potential beneficiaries could include behavioral health providers, addiction treatment centers, and telehealth platforms specializing in mental health (e.g., Talkspace ($TALK), LifeStance Health ($LFST)), but any impact would be years away and dependent on future appropriations. Currently, the bill does not name any private entity or create any mandate on for-profit companies.

Timeline: The bill has had zero legislative actions since introduction on March 9, 2026. There is no scheduled markup, no Senate companion, and no indication of near-term movement. For retail investors, this bill is not actionable.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.